Terumo

🏆We're thrilled to announce that our visionary leader, Antoinette Gawin, President and CEO of Terumo Blood and Cell Technologies, has been awarded the prestigious Denver Business Journal's Most Admired CEO award! This recognition celebrates exceptional executives shaping the #Denver community. 🩸Since taking the helm in 2019, Antoinette has guided Terumo BCT on a remarkable journey of growth and innovation, all while honoring our deep heritage of serving blood banks and #blooddonors worldwide. Under her leadership, we serve customers in over 160 countries, and we've expanded beyond our core business foundations to serve rapidly growing areas of #healthcare, including the cell and gene therapy and plasma innovations markets. We've also strengthened our global manufacturing capabilities and introduced a dedicated Patient Access Team to ensure seamless care. In addition to leading Terumo BCT, she chairs AdvaMed’s Technology and Regulation Committee and serves as a Trustee of The Conference Board's Committee for Economic Development. Antoinette's unwavering commitment to excellence and her passion for improving #healthcare drive our success. We're incredibly proud of her achievements and grateful for her #leadership. Join us in congratulating Antoinette on this well-deserved honor! ➡️ https://bit.ly/3NbW9Ow #MostAdmiredCEO #TerumoProud #Innovation #Colorado #LakewoodCO

See how we’re tackling inequities in healthcare in the latest episode of Terumo’s “Our Solutions” Series. Koenraad Dierick, MBA of Terumo Blood and Cell Technologies (Terumo BCT) shares how we tackle medical access inequalities at Terumo. Discover the crucial role of the Patient Access Team, understand the challenges in healthcare equity, and learn about our proactive measures for a more inclusive future. 🎥 Tune in for insights on how Terumo BCT is improving patient accessibility for all

Going Beyond the Boundaries of a Medical Device Manufacturer to Create Innovative and Comprehensive Solutions for Ever-Changing Healthcare Challenges   Guided by its Group Mission of “Contributing to Society through Healthcare,” #Terumo delivers high-quality products and services to patients and medical settings in over 160 countries and regions.   Our goal is to contribute to the advancement of healthcare and the enhancement of patients’ quality of life by addressing various healthcare challenges.   In recent years, rapid changes in the social environment have led to increasingly complex healthcare challenges. These include an increase in chronic diseases due to an aging population, the drive to improve healthcare efficiency through digital technologies, and the need to strike a balance between advancing healthcare, led by the progress of biopharmaceutical and genomic medicine, and pursing cost effectiveness.   To address these challenges in collaboration with medical settings and bring greater value to society, Terumo is committed to constantly transforming itself and going beyond the boundaries of a medical device manufacturer.   Utilizing unparallel quality and innovation enabled by our proven technologies, we go beyond simply offering products and services to create innovative and comprehensive solutions that effectively tackle the healthcare challenges of today and tomorrow.   This year marks the midpoint of GS26, our five-year growth strategy. With our 30,000 associates, we continue our relentless pursuit of becoming a company that the world truly needs, focusing on achieving the goals of GS26 and envisioning the future ahead.   We ask for your continued understanding and support in this endeavor.

Explore Terumo’s healthcare education and training innovations in the latest episode from Terumo’s “Our Solutions” Series. Minoru Ueno, General Manager of Terumo Medical Pranex, sheds light on how we’re revolutionizing medical education and training. Dive into our innovative solutions, understand the global challenges of medical settings, and discover our forward-thinking objectives. 🎥 Tune in for insightful perspectives in healthcare education.

Explore digital transformations in healthcare with the latest episode from #Terumo’s “Our Solutions” Series.   Sudipta Ghosh, APAC Regional Executive at Terumo Asia Holdings’ Medical Care Solutions Company (TMCS), shares how we’re driving digital transformations in hospitals and innovating for better care. Discover Terumo’s approach to digital solutions, how TMCS are realizing its brand promise of "Quality time for better care," and our future digital strategies.   🎥 Tune in for expert insights on digital innovation in global healthcare.

On September 13th in Tokyo, #Terumo held the company event “Terumo Patient’s Day 2024” to coincide with Terumo’s founding anniversary on September 17th. Through talks from doctors and patients, #TerumoAssociates recognized that our works connect and contribute to medical settings. “Terumo Patient’s Day” was celebrated not only in Japan but also at #TerumoGroup offices across the world. Learn more about our event below👇 https://lnkd.in/gRPBCsCy #healthcare #proudtobeTerumo

Starting today, MicroVention is now Terumo Neuro. This name change signifies a new chapter in the company’s evolution while maintaining its unwavering commitment to the creation and commercialization of groundbreaking innovations in neurovascular care. Learn more at the press release: https://lnkd.in/gUQ9kUAZ #TerumoNeuro #Terumo #StrongerTogether #Rebranding #Innovation #Neurointervention #Neurovascular #Neuro #Healthcare #Stroke #brainaneurysm

CEO, Hikaru Samejima, had a meeting with H.E. Mr. Rahm Emanuel, Ambassador Extraordinary and Plenipotentiary of the United States of America. It was an honor for #Terumo to receive an invitation to Ambassador’s Official Residence. His Excellency showed great interest in the healthcare industry and posed numerous inquiries regarding Terumo's current business standing and future prospects. #USA #USAmbassador

Innovation and Commitment: The History of Terumo - Acceleration of global development (Since the 1990s) (5/5) Terumo’s global development rapidly accelerated during the 1990s. Starting with the acquisition of the cardiovascular division from 3M in the United States in 1999, the Terumo Group has expanded its global presence by incorporating various overseas companies from different fields.  🔹In 2002, Vascutek Ltd. (U.K.), a manufacturer of vascular grafts, joined the Terumo Group.  🔹In 2006, MicroVention Inc. (U.S.), a neurovascular intervention device company, Joined the Terumo Group.  🔹In 2011, CaridianBCT Holding Corp. (currently Terumo Blood and Cell Technologies), a global leader in the blood transfusion industry, and neurovascular intervention device company, joined the Terumo Group. From the 2000s, Terumo deepened its focus to provide solutions for diverse issues, such as improving the quality of life of patients with chronic diseases, and enhancing the safety and efficacy of medical settings.  Terumo has been providing new treatment options, through its advancement in regenerative medicine, expansion of intravascular intervention possibilities, and strengthening blood and cell therapy technologies. #ProudtobeTerumo #History 

Innovation and Commitment: The History of Terumo - Full-scale Entry into the Artificial Organ Field and Development of Core Technologies (1970-80s) (4/5) In the 1970s, Terumo actively expanded its field of contribution to the global. Starting with the launch of the hollow fiber-dialyzer in 1977, Terumo made a full-scale entry into the artificial organ field in the 1980s. Numerous core technologies were developed at this time, including:  🔹The world's first microporous hollow-fiber membrane oxygenator  🔹Angiographic catheter systems  These technologies continue to be an integral part of the current product portfolio. Terumo continued to evolve by producing products that reduce the physical burden on patients. #ProudtobeTerumo #History